GrĂĽnwald, V. http://orcid.org/0000-0003-2083-7687
Bergmann, L.
Brehmer, B.
Eberhardt, B.
Kastrati, Karin
Gauler, T.
Gehbauer, G.
Gschwend, J.
Johannsen, M.
Klotz, T.
Protzel, C.
Schenck, M.
Staehler, M.
Funding for this research was provided by:
Deutsche Krebshilfe (German Guidelines in Oncology Program)
Universitätsklinikum Essen
Article History
Received: 23 April 2021
Accepted: 8 April 2022
First Online: 13 May 2022
Declarations
:
: VG: received research support, personal fees from Astra Zeneca, Bristol-Myers Squibb, MSD Sharp & Dohme, Ipsen, Pfizer. Personal fees from Merck Serono, EUSAPharm, Novartis, Lilly, Eisai, Roche, Janssen-Cilag. LB: no conflicts of interest to declare that are relevant to the content of this article. BB: received personal fees from BMS, Novartis, Pfizer.BE: received personal fees from GSK, Pfizer. TG: received personal fees from BMS, Merck Serono, MSD, Ipsen, Novartis, EISAI. GG: received personal fees from Ipsen, AstraZeneca, BMS. JG: received personal fees from Bayer, Roche, MSD, Janssen, Amgen, BMS. KK: no conflicts of interest to declare that are relevant to the content of this article. MJ: received personal fees from Pfizer, BMS, Janssen-Cilag, Hexal, EISAI, Sanofi, Bayer, Novartis, Astellas, Medac, Roche. TK: received personal fees from Janssen-Cilag, Bayer, Astellas, Pfizer, BMS, Novartis. CP: received personal fees from MSD. MS: no conflicts of interest to declare that are relevant to the content of this article. MStae: received personal fees from Pfizer, GSK, Novartis, Bayer, Roche, Aveo, EUSAPharm, Astellas, Ipsen, Exelexis, Pelleton, EISAI.
: This is a systematic review and consensus approach that assessed the value of existing data in regard to its clinical applicability. All data comes from published evidence from trials that followed current ethical standards. We did not generate new data at any stage of our process. This paper does not apply to an ethics committee approval. There is no indication for an informed consent of patients.